Acetylon Pharmaceuticals, Inc., a Boston, MA-based company that discovers and develops drugs to treat cancer, autoimmune and other diseases, has completed a $27m Series B equity financing.
Investors include new and existing private backers.
The company intends to use the funds for:
– advancement its lead drug candidate ACY-1215, a Class II-selective histone deacetylase (HDAC) inhibitor – into Phase I/II clinical testing for patients with relapsed and relapsed-refractory multiple myeloma;
– preclinical advancement of its additional selective HDAC inhibitor drug candidates for non-cancer disease indications including autoimmune and other inflammatory diseases.
This equity financing complements a recent $4.9m in funding provided by The Leukemia & Lymphoma Society to support clinical development of ACY-1215.
Acetylon Pharmaceuticals is led by President, CEO and co-founder Walter C. Ogier.